Rev Esp Quimioter 2022; 35(2):178-191

Impact of the implementation of a Sepsis Code Program in medical patient management: a cohort study in an Internal Medicine ward

AZUCENA BAUTISTA HERNÁNDEZ, ENRIQUE DE VEGA-RÍOS, JORGE SERRANO BALLESTEROS, DANIEL USEROS BRAÑA, LAURA CARDEÑOSO DOMINGO, ANGELS FIGUEROLA TEJERINA, ANDRÉS VON WERNITZ TELEKI, DAVID JIMÉNEZ JIMÉNEZ, IGNACIO DE LOS SANTOS GIL, CARMEN SÁEZ BÉJAR

Published: 31 January 2022

http://www.doi.org/10.37201/req/132.2021

Introduction. Sepsis is the main cause of death in hospitals and the implementation of diagnosis and treatment bundles has shown to improve its evolution. However, there is a lack of evidence about patients attended in conventional units.
Methods. A 3-year retrospective cohort study was conducted. Patients hospitalized in Internal Medicine units with
sepsis were included and assigned to two cohorts according to Sepsis Code (SC) activation (group A) or not (B). Baseline and evolution variables were collected.
Results. A total of 653 patients were included. In 296 cases SC was activated. Mean age was 81.43 years, median Charlson comorbidity index (CCI) was 2 and 63.25% showed some functional disability. More bundles were completed in group A: blood cultures 95.2% vs 72.5% (p < 0.001), extended spectrum antibiotics 59.1% vs 41.4% (p < 0.001), fluid resuscitation 96.62% vs 80.95% (p < 0.001). Infection control at 72 hours was quite higher in group A (81.42% vs 55.18%, odds ratio 3.55 [2.48-5.09]). Antibiotic was optimized more frequently in group A (60.77% vs 47.03%, p 0.008). Mean in-hospital stay was 10.63 days (11.44 vs 8.53 days, p < 0.001). Complications during hospitalization appeared in 51.76% of patients, especially in group B (45.95% vs 56.58%, odds ratio 1.53 [1.12-2.09]). Hospital readmissions were higher in group A (40% vs 24.76%, p < 0.001). 28-day mortality was significantly lower in group A (20.95% vs 42.86%, odds ratio 0.33 [0.23-0.47]).
Conclusions. Implementation of SC seems to be effective in improving short-term outcomes in IM patients, although therapy should be tailored in an individual basis.

Rev Esp Quimioter 2022; 35(2):178-191 [Full-text PDF]